Hepatic drug clearance in patients with mild cystic fibrosis

被引:17
作者
Kearns, GL
Crom, WR
Karlson, KH
Mallory, GB
Evans, WE
机构
[1] UNIV ARKANSAS MED SCI HOSP, DEPT PEDIAT, LITTLE ROCK, AR 72205 USA
[2] ARKANSAS CHILDRENS HOSP, DIV PEDIAT CLIN PHARMACOL, LITTLE ROCK, AR USA
[3] ARKANSAS CHILDRENS HOSP, DIV PULM, LITTLE ROCK, AR USA
[4] ARKANSAS CHILDRENS HOSP, CYST FIBROSIS CTR, LITTLE ROCK, AR USA
[5] UNIV TENNESSEE, DEPT CLIN PHARM, MEMPHIS, TN USA
[6] UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA
[7] ST JUDE CHILDRENS RES HOSP, CTR PEDIAT PHARMACOKINET & THERAPEUT, MEMPHIS, TN 38105 USA
[8] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38105 USA
[9] WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA
[10] ST LOUIS CHILDRENS HOSP, ALLERGY PULM MED DIV, ST LOUIS, MO 63178 USA
关键词
D O I
10.1016/S0009-9236(96)90181-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The plasma disposition of three model substrates (lorazepam, indocyanine green, and antipyrine) and the formation clearance of antipyrine metabolites (3-hydroxymethylantipyrine, norantipyrine, and 4-hydroxyantipyrine) were evaluated in 15 subjects with mild cystic fibrosis and in 15 healthy control subjects, Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg). In contrast, the clearance of antipyrine was not significantly different (1.0 +/- 0.7 versus 0.8 a 0.3 ml/min/kg), but the formation clearance for 3-hydroxymethylantipyrine mas significantly greater in patients with cystic fibrosis, Lorazepam and antipyrine apparent steady-state volume of distribution were not different between groups, These results suggest that clearance of drugs that undergo conjugation (e.g., lorazepam) or biliary excretion (e.g., indocyanine green) is increased in patients with mild cystic fibrosis, In contrast, the increased formation clearance of only one antipyrine metabolite suggests that alterations in clearance of drugs metabolized by cytochrome P450 enzymes are substrate specific and isoform specific in patients with cystic fibrosis.
引用
收藏
页码:529 / 540
页数:12
相关论文
共 47 条
  • [1] DISPOSITION OF ANTIPYRINE AND ACETAMINOPHEN GIVEN ALONE AND IN COMBINATION TO HUMAN-SUBJECTS
    AWNI, WM
    STPETER, JV
    KOVARIK, JM
    MATZKE, GR
    [J]. PHARMACEUTICAL RESEARCH, 1990, 7 (02) : 204 - 207
  • [2] GUIDE TO DRUG-DOSAGE IN HEPATIC-DISEASE
    BASS, NM
    WILLIAMS, RL
    [J]. CLINICAL PHARMACOKINETICS, 1988, 15 (06) : 396 - 420
  • [3] CAESAR J, 1961, CLIN SCI, V21, P43
  • [4] THE PATHOLOGICAL CHANGES IN THE LIVER IN CYSTIC FIBROSIS OF THE PANCREAS
    CRAIG, JM
    HADDAD, H
    SHWACHMAN, H
    [J]. AMA JOURNAL OF DISEASES OF CHILDREN, 1957, 93 (04): : 357 - 369
  • [5] DEFICIENT NIFEDIPINE OXIDATION - A RARE INHERITED TRAIT ASSOCIATED WITH CYSTIC-FIBROSIS KINDREDS
    DALY, AK
    SALH, BS
    BILTON, D
    ALLEN, J
    KNIGHT, AD
    WEBB, AK
    BRAGANZA, JM
    IDLE, JR
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 19 - 24
  • [6] DARGENIO D, 1992, ADAPT 2 USERS GUIDE
  • [7] EFFECT OF HEPARIN ADMINISTRATION ON PLASMA-BINDING OF BENZODIAZEPINES
    DESMOND, PV
    ROBERTS, RK
    WOOD, AJJ
    DUNN, GD
    WILKINSON, GR
    SCHENKER, S
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (02) : 171 - 175
  • [8] ENGEL G, 1994, P 14 EUR WORKSH DRUG, P282
  • [9] ENGEL G, 1994, Z GASTROENTEROL, V32, P51
  • [10] DRUG-METABOLISM IN EXTRAHEPATIC DISEASES
    FARRELL, GC
    [J]. PHARMACOLOGY & THERAPEUTICS, 1987, 35 (03) : 375 - 404